1321 related articles for article (PubMed ID: 20152998)
21. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
22. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.
Zander M; Madsbad S; Deacon CF; Holst JJ
Diabetologia; 2006 Feb; 49(2):369-74. PubMed ID: 16385384
[TBL] [Abstract][Full Text] [Related]
23. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
25. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
[TBL] [Abstract][Full Text] [Related]
26. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
27. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
[TBL] [Abstract][Full Text] [Related]
28. Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.
Gustavson SM; Dai H; Preston GM; Somayaji V; Hirshberg B; Calle RA
Diabetes Res Clin Pract; 2011 Feb; 91(2):e45-9. PubMed ID: 21130513
[TBL] [Abstract][Full Text] [Related]
29. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
30. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
31. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
32. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
Mulherin AJ; Oh AH; Kim H; Grieco A; Lauffer LM; Brubaker PL
Endocrinology; 2011 Dec; 152(12):4610-9. PubMed ID: 21971158
[TBL] [Abstract][Full Text] [Related]
34. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
Wu T; Thazhath SS; Bound MJ; Jones KL; Horowitz M; Rayner CK
Diabetes Res Clin Pract; 2014 Oct; 106(1):e3-6. PubMed ID: 25172519
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
[TBL] [Abstract][Full Text] [Related]
37. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
38. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
[TBL] [Abstract][Full Text] [Related]
39. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
40. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
